Medizinische Hochschule Hannover
Welcome,         Profile    Billing    Logout  
 330 Trials 
1256 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contact, Site Public
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
N/A
50
Europe
No intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
06/27
06/27
NRG-CC011, NCT05896189: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Recruiting
N/A
386
US
Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games
NRG Oncology, National Cancer Institute (NCI)
Breast Cancer, Cognitive Impairments
02/27
11/27
NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Recruiting
N/A
600
RoW
Takeda
Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD)
11/27
11/27
NCT06002828: Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Recruiting
N/A
2000
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
02/30
02/30
NCT03630536: TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

Recruiting
N/A
500
US
Children's Hospital Medical Center, Cincinnati
Renal Cell Carcinoma
05/28
05/28
NCT05705531: A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Recruiting
N/A
230
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Survey Administration
Children's Oncology Group, National Cancer Institute (NCI)
Cardiovascular Disorder, Clonal Hematopoiesis, Hodgkin Lymphoma
10/28
10/28
NCT05702645: A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Recruiting
N/A
330
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Clinical Evaluation, Clinical Assessment, Questionnaire Administration, Survey Administration
Children's Oncology Group, National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome
12/28
12/28
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting
N/A
207
Europe, US, RoW
ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855
Baxalta now part of Shire
Hemophilia A
02/30
02/30
EA2185, NCT04239573: Comparing Two Methods to Follow Patients With Pancreatic Cysts

Recruiting
N/A
4606
Canada, US, RoW
Computed Tomography, CAT, CAT scan, Computerized Axial Tomography, computerized tomography, CT, CT scan, tomography, Endoscopic Ultrasound, endosonography, EUS, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Pancreatic Carcinoma
07/33
07/33
PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting
N/A
1340
Europe, Canada, US
No intervention
Takeda, Takeda Development Center Americas, Inc.
Hypoparathyroidism
11/34
11/34
SWOG-S1703, NCT03723928: S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Recruiting
N/A
739
US, RoW
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, STMDDM, Quality-of-Life Assessment, Quality of Life Assessment, Anxiety Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
12/30
12/36
FORTE, NCT05080673: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Recruiting
N/A
9500
US
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
NRG Oncology, National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
11/35
11/65
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
NCT00904241: Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Recruiting
N/A
10000
Europe, Canada, US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
01/00
 
AREN03B2, NCT00898365: Study of Kidney Tumors in Younger Patients

Recruiting
N/A
8000
Europe, Canada, US, RoW
Cytology Specimen Collection Procedure, Cytologic Sampling, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Adult Cystic Nephroma, Anaplastic Kidney Wilms Tumor, Angiolipoma, Cellular Congenital Mesoblastic Nephroma, Classic Congenital Mesoblastic Nephroma, Clear Cell Sarcoma of the Kidney, Congenital Mesoblastic Nephroma, Cystic Partially Differentiated Kidney Nephroblastoma, Diffuse Hyperplastic Perilobar Nephroblastomatosis, Extrarenal Rhabdoid Tumor, Kidney Medullary Carcinoma, Kidney Neoplasm, Kidney Oncocytoma, Kidney Wilms Tumor, Metanephric Adenofibroma, Metanephric Adenoma, Metanephric Stromal Tumor, Metanephric Tumor, Mixed Congenital Mesoblastic Nephroma, Ossifying Renal Tumor of Infancy, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Rhabdoid Tumor of the Kidney, Wilms Tumor
01/00
 
NCT00736749: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Recruiting
N/A
5000
US
Assessment of Therapy Complications, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
01/00
 
Seidler, Ursula
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Placebo
Takeda
Crohn's Disease
09/26
07/27
Staubach-Renz, Petra
NCT05561257: Vitamin C as add-on Therapy in Patients With Acute Herpes Zoster

Recruiting
2
76
Europe
Vitamin C
Pascoe Pharmazeutische Praeparate GmbH
Neuropathic Pain
01/25
01/25
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Recruiting
2
99
Europe, Canada, US, RoW
Placebo/Daxdilimab, Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus
07/24
12/24
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
114
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
01/25
02/25
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis

Hourglass Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis
Completed
1
24
Europe, US
CDX-0159, barzolvolimab, Normal saline
Celldex Therapeutics
Prurigo Nodularis
07/23
07/23
DEVISE, NCT06324695: Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases

Not yet recruiting
N/A
550
Europe
HautKompass
Universitätsklinikum Hamburg-Eppendorf, German Federal Ministry of Education and Research
Psoriasis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Atopic Dermatitis
09/24
03/25
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Recruiting
N/A
3000
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
01/27
01/27
Horiki, Noriyuki
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Klode, Joachim
NCT03683550: Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma

Active, not recruiting
N/A
836
Europe
SLNE with preoperative hybrid SPECT/CT, Standard SLNE
University Hospital, Essen
Melanoma
06/25
06/25
Stoll, Mattias
NCT03696160: The Late Presenter Treatment Optimisation Study

Active, not recruiting
3
447
Europe
Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals
HIV/AIDS
06/24
06/24
Könecke, Christian
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
03/24
03/24
Langhe, Ellen De
NCT04464434 / 2019-004718-32: Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

Recruiting
4
50
Europe
Upfront autologous HSCT
UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, Boehringer Ingelheim, Miltenyi Biotec, Inc.
Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse, Autologous Stem Cell Transplantation, Cyclophosphamide, Mycophenolate Mofetil, Treatment Strategy
09/25
10/30
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

Recruiting
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
Beutel, Gernot
IDUNN, NCT04629833 / 2019-001462-15: Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
12/25
12/27
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Recruiting
2
440
Europe, RoW
Allogeneic Stem Cell Transplantation
Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)
Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
11/22
11/24
VENreg, NCT03662724: Venetoclax Registry

Recruiting
N/A
100
Europe
Venetoclax, Venclyxto
Hannover Medical School
Acute Myeloid Leukemia
11/21
11/25
Ivanyi, Philipp
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
02/25
08/26
Terkamp, Christoph
PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting
N/A
1340
Europe, Canada, US
No intervention
Takeda, Takeda Development Center Americas, Inc.
Hypoparathyroidism
11/34
11/34
Kempf, Tibor
NCT03613246: NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population

Recruiting
N/A
200
Europe
NVT GmbH
Transcatheter Aortic Valve Implantation
12/24
02/25
NCT05601453: The ReTAVI Prospective Observational Registry

Recruiting
N/A
150
Europe, Canada, RoW
Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI
Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences
Aortic Valve Stenosis, Structural Valve Deterioration, Structural Valve Degeneration
09/25
12/26
NCT04398654: Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes

Recruiting
N/A
554
Europe
CardioMEMSTM HF sensor - pulmonary artery pressure measurement
IHF GmbH - Institut für Herzinfarktforschung
Heart Failure
06/26
12/26
Hoeglinger, Guenter
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Recruiting
2
735
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
11/27
02/30
Golpon, Heiko
NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Active, not recruiting
2
118
Europe
Brigatinib, Study treatment, Tyrosine kinase inhibitor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NSCLC
12/25
12/25
Mavroudis, Dimitrios
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Recruiting
3
860
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
04/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Recruiting
3
650
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
10/24
06/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
Wedi, Bettina
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
114
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
01/25
02/25
CALM-CIndU, NCT06050928: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Recruiting
1
30
Europe, Canada, US
Oral EP262
Escient Pharmaceuticals, Inc
Chronic Inducible Urticaria
09/24
11/24
BOUATTOUR, Mohamed
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting
2
105
Europe
Atezolizumab, Bevacizumab, UCPVax
Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE
Hepatocellular Carcinoma
04/25
09/27
SIROCHO, NCT05265208: Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Suspended
2
62
Europe
Capecitabine, L01BC06, Selective Internal Radiotherapy (SIRT), Surgery
Center Eugene Marquis
Resectable Intrahepatic Cholangiocarcinoma
09/27
02/30
NCT05733598: RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Not yet recruiting
2
60
Europe, US
RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
04/27
07/27
HESTIA, NCT05622071: Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions

Recruiting
2
50
Europe
Tislelizumab, BGB-A317
UNICANCER
Hepatocellular Carcinoma by BCLC Stage
11/27
04/28
COVID19-CHIEF, NCT04367805: COVID-19 Infection in Patients With Hepatocellular Carcinoma

Active, not recruiting
N/A
23
Europe
nasopharyngeal Covid 19 RT-PCR
Centre Hospitalier Universitaire, Amiens, Centre Hospitalier-Universitaire Bondy, University Hospital, Bordeaux, Centre Hospitalier-Universitaire CLICHY, Centre Hospitalier Général CORBEIL-ESSONNE, CHU CRETEIL, University Hospital, Grenoble, University Hospital, Lille, CHU LYON, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Toulouse, CHU VILLEJUIF, Central Hospital, Nancy, France, Centre Hospitalier Universitaire de Nice, University Hospital, Montpellier
Hepatocellular Carcinoma, COVID-19
10/23
10/24
OPERANDI-HCC, NCT06334965: Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Not yet recruiting
N/A
180
Europe
Simultaneous 18F-Choline PET-MRI
Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Radioembolization
11/27
09/29
TARGETMONITO, NCT05443087: TARGETed Therapy Drug MONITOring in DIGestive Oncology

Recruiting
N/A
330
Europe
Blood sampling to build population pharmacokinetics model
UNICANCER
Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors
08/26
06/27
SIRtain, NCT05967143: Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors ( Registry)

Recruiting
N/A
845
Europe
SIRT
Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
06/28
06/29
Reuter, Christoph
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
Suehs, Kurt-Wolfram
Generate-Boost, NCT03993262: Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

Recruiting
2
50
Europe
Bortezomib, Placebo, isotonic NaCl solution
Jena University Hospital
Autoimmune Encephalitis
11/25
04/26
Limb, James
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Placebo, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, National Intensive Care Surveillance MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
Kalla, Mukesh
NCT05872269: A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Recruiting
4
1500
RoW
Saroglitazar
Zydus Lifesciences Limited
NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias, Metabolic Syndrome
01/25
06/25
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Schmidt, Bernhard MW
Genius, NCT05282732: Retrospective Analysis of Performance and Treatment Data Collected for SleddFlux Filter, Ultraflux AV 600 S Filter & 90 Concentrates in Haemodialysis Patients

Recruiting
N/A
100
Europe
Fresenius Medical Care Deutschland GmbH, Alcedis GmbH
Renal Failure, End Stage Renal Disease, Acute Renal Failure
12/24
12/24
Sander, Annette
HIT-HGG-2013, NCT03243461 / 2013-004187-56: International Cooperative Phase III Trial of the HIT-HGG Study Group

Recruiting
3
167
Europe
Temozolomide + Valproic Acid
University of Göttingen, Deutsche Kinderkrebsstiftung, Hannover Medical School
Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma, Gliomatosis Cerebri
12/23
12/23
MyPal4Kids, NCT04381221: Observational MyPal-Child Study on the ePRO-based Early Palliative Care Digital System in Paediatric Oncology Patients

Recruiting
N/A
100
Europe, RoW
Centre for Research and Technology Hellas, Universität des Saarlandes, Brno University Hospital, Hannover Medical School
Leukemia, Childhood, Solid Tumor, Childhood
09/22
09/22
Grode, Leander
NCT04387409 / 2020-001376-15: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Active, not recruiting
3
59
Europe
VPM1002, Placebo
Vakzine Projekt Management GmbH, FGK Clinical Research GmbH
Infection, Respiratory Tract
05/21
05/21
Liang, Xinjun
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Not yet recruiting
3
528
RoW
Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
10/23
12/23
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Not yet recruiting
3
190
RoW
HX008, Investigator's Choice Chemotherapy
Taizhou Hanzhong biomedical co. LTD
Metastatic Colorectal Cancer
01/26
10/28
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Recruiting
3
680
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
03/26
07/28
NCT05188209: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Recruiting
2
60
RoW
MRG003
Shanghai Miracogen Inc.
Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma
03/23
08/23
NCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Recruiting
1/2
364
RoW
SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies
Jiangsu HengRui Medicine Co., Ltd.
HER2-expressing Advanced Solid Tumors
11/26
12/26
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms

Recruiting
1
94
RoW
LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus
Taizhou HoudeAoke Biomedical Co., Ltd.
Digestive System Neoplasms
06/21
06/22
KY-0118-ZJKY, NCT06175780: Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
189
RoW
KY-0118
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Neoplasms, Neoplasms by Histologic Type
12/25
12/25
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Active, not recruiting
1
208
US, RoW
BB-1701
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Locally Advanced/Metastatic HER2 Positive Solid Tumors
08/24
12/24
CLINCH, NCT05718895: A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

Recruiting
1
156
RoW
ATG-022
Antengene Biologics Limited
Advanced/Metastatic Solid Tumors
06/26
06/26
Hinneburg, Linda
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
Paduch, Anne
NCT04474678: Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")

Completed
N/A
240
Europe
"My Logbook! - I know my way around!"
Medical University of Vienna, St. Anna Kinderspital, Austria, Charite University, Berlin, Germany, Cnopfsche Kinderklinik, Nürnberg, Kepler University Hospital, University Hospital, Saarland, Hannover Medical School, Krankenhaus Bozen, Goethe University, Universitätsklinikum Hamburg-Eppendorf, Universitätsklinikum Leipzig, University Hospital Muenster, University Hospital Tuebingen, Salzburger Landeskliniken, Leuwaldhof St.Veit (Kinder- und Jugendreha), University Hospital, Essen, Medical University of Graz, University Hospital Erlangen, Wuerzburg University Hospital, Klinik Bad Oexen, Germany, Universitätsklinikum Köln, University Hospital Schleswig-Holstein, University Hospital Carl Gustav Carus, Universitätsmedizin Mannheim, University Hospital Regensburg, Luca-Dethlefsen-Hilfe e.V., Insel Gruppe AG, University Hospital Bern, Staedtisches Klinikum Karlsruhe
Brain Tumor, Neurofibromatoses, Sarcoma, Leukemia, Hematologic Diseases, Neuroblastoma
12/23
12/23
Schrader, Christoph
FEEMSA, NCT04706234: Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies

Recruiting
N/A
200
Europe, Japan, RoW
Kliniken Beelitz GmbH, University Hospital Muenster, Medical University of Warsaw, University Hospital Carl Gustav Carus, University of Ulm, Medical University Innsbruck, Hannover Medical School, University of Barcelona
Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy
12/23
07/24
Craciun, Eugeniu
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Strauss, Maria
RESTORE-LIFE, NCT03320304: A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

Recruiting
N/A
500
Europe
Vagal Nerve Simulation (VNS) Therapy
LivaNova
Treatment Resistant Depression
12/26
12/28
 

Download Options